Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

NCT06449625 is registered in ClinicalTrials.gov with Klaus Gottlob Müller as lead sponsor.

NCT NCT06449625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
Lead sponsor
Klaus Gottlob Müller
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 12, 2024
Completion date
February 1, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic toxicity, inflammation, intestinal mucositis